Press Releases

Switch to mobile view »
3/1/2010
Mission Pharmacal Launches New Vitamin B6-Rich Prescription Prenatal Vitamin, CitraNatal® B-Calm New option with added vitamin B6 may help women who suffer from severe nausea and vomiting during their pregnancy Full Release»
3/1/2010
Mission Pharmacal Launches New Formulation of Kidney Stone Treatment, Urocit®-K 15 mEq (1620 mg) potassium citrate Maximum-strength, more convenient option available to help increase patient compliance Full Release»
9/10/2009
Mission Acquires Natafort® and Natachew™ from Warner Chilcott Full Release»
9/1/2009
Mission Pharmacal Acquires Dr. Smith's Diaper Ointment Full Release»
2/2/2009
Mission Pharmacal Celebrates Historic Milestone Pioneer in Women's Health Marks 64 Years of Innovation and Growth Full Release»
1/14/2009
Mission Pharmacal and Paladin Complete Agreement for Urocit®-K for the treatment of Kidney Stones Full Release»
12/8/2008
Mission Pharmacal Launches CitraNatal® Assure Prescription Prenatal Vitamin Designed to ensure comfort and optimize nutrition for women and their babies Full Release»
5/20/2008
Mission Pharmacal Launches Ferralet® 90 for Treatment of the Leading Cause of Anemia in the U.S. Designed to improve on existing oral iron therapies Full Release»
12/5/2007
Mission Pharmacal Sells Gold Standard Kidney Stone Diagnostic Tests to Quest Diagnostics Full Release»
8/30/2007
Mission Pharmacal Sells Citracal® Calcium Brand to Bayer HealthCare Plans Exciting Future as Specialty Pharmaceutical Company Full Release»
7/31/2007
New Study Finds Tindamax® To Be Effective, Well-Tolerated Treatment for Bacterial Vaginosis Full Release»
5/24/2007
FDA Approves Tindamax® for Bacterial Vaginosis First New Oral Treatment for Bacterial Vaginosis in a Decade Full Release»
11/13/2006
Centers for Disease Control and Prevention Recommends Tindamax® for the Treatment of Trichomoniasis in Latest Sexually Transmitted Disease Guidelines Full Release»
8/17/2006
Mission Pharmacal Submits Supplemental New Drug Application for Tindamax® (tinidazole) as Treatment of Bacterial Vaginosis Full Release»
5/9/2006
Most Common Curable STD a Significant Public Health Concern When Untreated, May Contribute to Spread of HIV New Web Resource Launched to Educate on Trichomoniasis Treatment Full Release»
5/8/2006
Mission Pharmacal Completes Phase III Study of Tindamax® for the Treatment of Bacterial Vaginosis Full Release»
4/20/2006
Mission Pharmacal Acquires Tindamax®: Treatment for Trichomoniasis, Most Common Non-Viral Sexually Transmitted Disease Potent, Well-Tolerated Therapy Allows Simple One-Day, One-Dose Regimen Full Release»
More than 500,000 babies are born too soon each year. Some are so small they struggle to survive. This year, Mission Pharmacal is joining forces with the March of Dimes* as a National Corporate Sponsor to help raise awareness about the growing crisis of premature birth. To learn more and help us fight prematurity, click on the links below. For more than 60 years, Mission Pharmacal has been committed to providing products for healthy women and healthy babies.
Learn moreDonate
Share on FacebookShare on MySpaceShare on TwitterShare on DiggShare on Yahoo! Buzz
Share on StumbleUponShare on redditShare on TechnoratiShare on del.icio.usShare on LinkedIn